Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy

Ying Dong,1 Jing Gao,1 Mengyue Pei,2 Xiaoli Wang,2 Chuangnian Zhang,2 Yingjie Du,1 Yanjun Jiang1 1School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300130, People’s Republic of China; 2Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dong Y, Gao J, Pei M, Wang X, Zhang C, Du Y, Jiang Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	antigen delivery silica solid sphere nanovaccine cancer immunotherapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3d314abff5cc43cf911765021ef97428
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3d314abff5cc43cf911765021ef97428
record_format	dspace
spelling	oai:doaj.org-article:3d314abff5cc43cf911765021ef974282021-12-02T15:25:44ZAntigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy1178-2013https://doaj.org/article/3d314abff5cc43cf911765021ef974282020-04-01T00:00:00Zhttps://www.dovepress.com/antigen-conjugated-silica-solid-sphere-as-nanovaccine-for-cancer-immun-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Ying Dong,1 Jing Gao,1 Mengyue Pei,2 Xiaoli Wang,2 Chuangnian Zhang,2 Yingjie Du,1 Yanjun Jiang1 1School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300130, People’s Republic of China; 2Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, People’s Republic of ChinaCorrespondence: Jing Gao; Xiaoli Wang Tel +86-22-60204945; +86-22-87890151Email jgao@hebut.edu.cn; wangxl@bme.pumc.edu.cnBackground: Nanocarriers could deliver significantly higher amounts of antigen to antigen-presenting cells (APCs), which have great potential to stimulate humoral and cellular response in cancer immunotherapy. Thereafter, silica solid nanosphere (SiO2) was prepared, and a model antigen (ovalbumin, OVA) was covalently conjugated on the surface of SiO2 to form nanovaccine (OVA@SiO2). And the application of OVA@SiO2 for cancer immunotherapy was evaluated.Materials and Methods: SiO2 solid nanosphere was prepared by the Stöber method, then successively aminated by aminopropyltriethoxysilane and activated with glutaraldehyde. OVA was covalently conjugated on the surface of activated SiO2 to obtain nanovaccine (OVA@SiO2). Dynamic light scattering, scanning electron microscope, and transmission electron microscope were conducted to identify the size distribution, zeta potential and morphology of OVA@SiO2. The OVA loading capacity was investigated by varying glutaraldehyde concentration. The biocompatibility of OVA@SiO2 to DC2.4 and RAW246.7 cells was evaluated by a Cell Counting Kit-8 assay. The uptake of OVA@SiO2 by DC2.4 and its internalization pathway were evaluated in the absence or presence of different inhibitors. The activation and maturation of bone marrow-derived DC cells by OVA@SiO2 were also investigated. Finally, the in vivo transport of OVA@SiO2 and its toxicity to organs were appraised.Results: All results indicated the successful covalent conjugation of OVA on the surface of SiO2. The as-prepared OVA@SiO2 possessed high antigen loading capacity, which had good biocompatibility to APCs and major organs. Besides, OVA@SiO2 facilitated antigen uptake by DC2.4 cells and its cytosolic release. Noteworthily, OVA@SiO2 significantly promoted the maturation of dendritic cells and up-regulation of cytokine secretion by co-administration of adjuvant CpG-ODN.Conclusion: The as-prepared SiO2 shows promising potential for use as an antigen delivery carrier.Keywords: antigen delivery, silica solid sphere, nanovaccine, cancer immunotherapyDong YGao JPei MWang XZhang CDu YJiang YDove Medical Pressarticleantigen deliverysilica solid spherenanovaccinecancer immunotherapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 2685-2697 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	antigen delivery silica solid sphere nanovaccine cancer immunotherapy Medicine (General) R5-920
spellingShingle	antigen delivery silica solid sphere nanovaccine cancer immunotherapy Medicine (General) R5-920 Dong Y Gao J Pei M Wang X Zhang C Du Y Jiang Y Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
description	Ying Dong,1 Jing Gao,1 Mengyue Pei,2 Xiaoli Wang,2 Chuangnian Zhang,2 Yingjie Du,1 Yanjun Jiang1 1School of Chemical Engineering and Technology, Hebei University of Technology, Tianjin 300130, People’s Republic of China; 2Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300192, People’s Republic of ChinaCorrespondence: Jing Gao; Xiaoli Wang Tel +86-22-60204945; +86-22-87890151Email jgao@hebut.edu.cn; wangxl@bme.pumc.edu.cnBackground: Nanocarriers could deliver significantly higher amounts of antigen to antigen-presenting cells (APCs), which have great potential to stimulate humoral and cellular response in cancer immunotherapy. Thereafter, silica solid nanosphere (SiO2) was prepared, and a model antigen (ovalbumin, OVA) was covalently conjugated on the surface of SiO2 to form nanovaccine (OVA@SiO2). And the application of OVA@SiO2 for cancer immunotherapy was evaluated.Materials and Methods: SiO2 solid nanosphere was prepared by the Stöber method, then successively aminated by aminopropyltriethoxysilane and activated with glutaraldehyde. OVA was covalently conjugated on the surface of activated SiO2 to obtain nanovaccine (OVA@SiO2). Dynamic light scattering, scanning electron microscope, and transmission electron microscope were conducted to identify the size distribution, zeta potential and morphology of OVA@SiO2. The OVA loading capacity was investigated by varying glutaraldehyde concentration. The biocompatibility of OVA@SiO2 to DC2.4 and RAW246.7 cells was evaluated by a Cell Counting Kit-8 assay. The uptake of OVA@SiO2 by DC2.4 and its internalization pathway were evaluated in the absence or presence of different inhibitors. The activation and maturation of bone marrow-derived DC cells by OVA@SiO2 were also investigated. Finally, the in vivo transport of OVA@SiO2 and its toxicity to organs were appraised.Results: All results indicated the successful covalent conjugation of OVA on the surface of SiO2. The as-prepared OVA@SiO2 possessed high antigen loading capacity, which had good biocompatibility to APCs and major organs. Besides, OVA@SiO2 facilitated antigen uptake by DC2.4 cells and its cytosolic release. Noteworthily, OVA@SiO2 significantly promoted the maturation of dendritic cells and up-regulation of cytokine secretion by co-administration of adjuvant CpG-ODN.Conclusion: The as-prepared SiO2 shows promising potential for use as an antigen delivery carrier.Keywords: antigen delivery, silica solid sphere, nanovaccine, cancer immunotherapy
format	article
author	Dong Y Gao J Pei M Wang X Zhang C Du Y Jiang Y
author_facet	Dong Y Gao J Pei M Wang X Zhang C Du Y Jiang Y
author_sort	Dong Y
title	Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
title_short	Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
title_full	Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
title_fullStr	Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
title_full_unstemmed	Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
title_sort	antigen-conjugated silica solid sphere as nanovaccine for cancer immunotherapy
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/3d314abff5cc43cf911765021ef97428
work_keys_str_mv	AT dongy antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT gaoj antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT peim antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT wangx antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT zhangc antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT duy antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy AT jiangy antigenconjugatedsilicasolidsphereasnanovaccineforcancerimmunotherapy
_version_	1718387197778853888

Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy

Ejemplares similares